Author: CoRegen, Inc.

CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform

March 17, 2026

CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform